A prospective and randomized study comparing the use of alarms, desmopressin and imipramine in the treatment of monosymptomatic nocturnal enuresis.

Autor: Mello MF; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil. Electronic address: marcos.urologia@gmail.com., Locali RF; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil., Araujo RM; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil., Reis JN; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil., Saiovici S; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil., Mello LF; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil., Trigo Rocha FE; Pediatric Urology Unit, Division of Urology, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Journal of pediatric urology [J Pediatr Urol] 2023 Jun; Vol. 19 (3), pp. 241-246. Date of Electronic Publication: 2023 Jan 11.
DOI: 10.1016/j.jpurol.2023.01.004
Abstrakt: Background: Monosymptomatic enuresis (MNE) results from a pathogenic triad that may include lack of vasopressin secretion during sleep, reduced functional bladder capacity and inability to wake up during sleep. The treatment of MNE can be performed through behavioral therapy, use of alarms or medications such as desmopressin and imipramine.
Objective: To compare the effectiveness of different treatments of MNE.
Study Design: Prospective and randomized study comparing different intervention and a control group (receiving only behavior therapy) for MNE.
Inclusion Criteria: age between 5 and 16 years old, with MNE, evaluated at the pediatric urology outpatient clinic of Hospital Infantil Menino Jesus. At first visit children were submitted to behavior therapy (urotherapy) for 3 months, children were subsequently characterized according to the ICCS as non-responders, partial responders, or full responders. Those partial responders or non-responders received a patient ID and were randomized to four groups: Alarm Group (G1), Desmopressin Group - DDAVP (G2), Imipramine Group (G3) and Control (G4). All groups were monitored monthly, for a period of 6 months. After 6 months, the children were reevaluated for MNE.
Results: 93 patients were enrolled. Mean age was 10.96 years with a standard deviation of 2.28 years, 59,1% were male. All groups had improvement in the number of dry nights (Table). Taking in account success the population full responders and partial responders: Alarm Group (G1) achieve success in 100% of cases, Desmopressin Group - DDAVP (G2) in 63.6% of cases, Imipramine Group (G3) in 73.7% of cases (Table 3). No drugs side effects were observed in both groups (G2 and G3), there was no dropout in patients who used alarms.
Discussion: Our data suggests that the use of alarms is the most effective treatment of ENM with superior results when compared to imipramine and DDAVP. The small number of participants is a weakness of the study, as well as the lack of a voiding diary at the end of the study.
Conclusion: All therapeutics options utilized in the treatment of MNE are safe, effective and has a low rate of abandonment.
(Copyright © 2023 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: